Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to better understand if transesophageal echocardiography during cardiac surgery can predict problems with kidney function after cardiac surgery.


Clinical Trial Description

Informed consent will be obtained prior to surgery. Preoperative demographic and baseline clinical data will be collected. We will assess the patient's risk of postoperative AKI using the validated Cleveland clinic score based on preoperative risk factors and calculate the European System Operative Score Risk Evaluation score (EuroSCORE II). After standard anesthesia induction and intubation, a TEE probe will be inserted by a cardiac anesthesiologist, who is certified in intraoperative echocardiography. We will use a standard ultrasound machine (EPIQ 7 Philips;Philips, Bothell, WA). Images of the right or left kidney along with Doppler flow and velocities will be obtained prior to cardiopulmonary bypass (CPB), after CPB, and after chest closure. Images of the portal vein with Doppler flow and velocity will be obtained prior to CPB, after CPB, and after chest closure. Vitals signs and hemodynamic data will be collected concurrently during these times. (See Data Sheet) Concurrent ECG will be obtained to identify the phases of the cardiac cycle. Mean arterial pressure (MAP) will be maintained within 20% of baseline MAP with bolus or continuous infusion of vasopressors (phenylephrine, norepinephrine, epinephrine, vasopressin, ephedrine). Cardiopulmonary bypass management will be standard, with target systemic blood flow of 2.4L/min/m2. Postoperative data will include urine output, serum creatinine, calculated GFR (using Modification of Diet in Renal Disease [MDRD] method) hospital and ICU length of stay, and 30-day mortality. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04112953
Study type Observational
Source University of Chicago
Contact
Status Completed
Phase
Start date September 4, 2019
Completion date November 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Active, not recruiting NCT04008810 - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Recruiting NCT04597034 - Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19 N/A
Completed NCT04458571 - Effect of CRRT Duration on Solute Removal
Recruiting NCT04114747 - Renal Physiology During Continuous Renal Replacement Therapy N/A
Completed NCT05094154 - Effect of Antibiotic Choice On ReNal Outcomes (ACORN) Phase 4
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Not yet recruiting NCT05382078 - Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Recruiting NCT04351906 - Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome N/A
Completed NCT04762524 - The Impact of CRRT Modality on Filter Life N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Completed NCT04788394 - Renal Involvement in Hospitalized Children With COVID-19
Recruiting NCT04474249 - Follow-up of Critical COVID-19 Patients
Recruiting NCT04517630 - Renal Biomarkers in AKI and COVID-19
Completed NCT04407156 - Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom
Recruiting NCT04895384 - El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)
Completed NCT03070353 - Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury Phase 2/Phase 3
Completed NCT03391830 - Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy N/A
Recruiting NCT04216927 - NO During CPB in Neonates to Reduce Risk of AKI Phase 3